KLK3 and bone metastasis: Our study showed that early treatment discontinuation (cycles 1–2) versus later (≥3 cycles) had a greater proportion of patients with the following characteristics at baseline: high median PSA levels, poor ECOG PS, radiation therapy for bone metastasis, liver and lung metastasis lesions and taxane treatment as most recent prior therapy.